Anti-Human CCR4 (Mogamulizumab Biosimilar)
Catalog #500038
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500038 | 1 mg | $250.00 | ||
| 500038 | 5 mg | $750.00 | ||
| 500038 | 20 mg | $2,500.00 |
Product Details
Minretumomab is a murine monoclonal antibody that specifically targets tumor-associated glycoprotein 72 (TAG-72), a biomarker commonly expressed in various epithelial tumors, including colorectal, ovarian, breast, and pancreatic cancers. This biosimilar is widely used in oncology research, tumor detection, and targeted cancer therapy studies.
Specifications
| Clone | Mogamulizumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human CCR4 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |